Nitric Oxide (“NO”) is a critical endogenous signaling molecule in cardiovascular health and disease acting as a potent inducer of smooth muscle relaxation in blood vessels thereby regulating the vascular tone and blood flow.  Inhaled nitric oxide (“iNO”) has gained significant prominence in treating highly debilitating hypoxic lung failure due to persistent pulmonary hypertension in newborns, pulmonary arterial hypertension and pulmonary hypertension associated with pulmonary diseases.  However, the market for current tank-based iNO delivery systems is limited due to cost, complexity, and limited availability.

Groundbreaking discoveries by iNOvodel founders provide a simpler, safer, compact, portable and more versatile means of generating and delivering iNO, offering the promise of lower cost and better treatment for existing iNO therapy, and the potential for a significant expansion of the patient population who can safely and effectively benefit from it.